CANCER AND LEUKEMIA GROUP B

描述(改编自申请人的摘要)：自年成立以来 1993年，马萨诸塞大学癌症中心曾试图澄清 对正常和癌细胞生物学的新见解。以美国为基地的调查人员 MASS开始将这些知识转化为临床相关知识 通过CALGB进行的研究和治疗方法。例如，Dr。 Mary-Ellen Taplin描述了特定的雄激素受体基因突变 这可能针对激素非依赖性前列腺癌的更有效的治疗 癌症。这些初步研究构成了受资助的相关研究之一 通过CALGB进行科学研究，并由CALGB核心实验室之一组成。 基于我们在造血细胞生物学方面的经验和坚实基础， 华盛顿大学大众癌症中心的一个主要关注点是移植生物学。 努力集中在(1)确定促进嫁接的因素， (2)开发全新的移植模型，使用最少的 清髓，(3)脐血移植，(4)NOD-SCID临床前 检测微小残留病的移植模型，以及(5)基因治疗 将MDR1转移到正常的造血干细胞等途径。许多 《造血干细胞生物学原理》现正被应用于 固体器官系统，密歇根大学的研究人员正在评估生长 通过定义正常细胞和肿瘤细胞的特征 实体瘤系统中的恶性干细胞和定义自分泌和 旁分泌环路的生长控制。“干细胞”在乳房的研究 癌症、前列腺癌和胶质母细胞瘤“正在进行中，并可能提供 作为CALGB配套研究的重要临床相关研究 治疗方案。我们的小组活动和科学贡献 在过去的四年里显著增加了。U大众调查员在 CALGB对移植、乳房方面的活动做出了重大贡献 癌症、前列腺癌、外科手术和胃肠癌。 通过审计委员会和其他特设机构提供的行政捐款 委员会的规模一直很大。重大努力已导致改善 对小组研究的应计收益和对#年提交的数据质量的改进 CALGB临床试验。

DESCRIPTION (adapted from the applicant's abstract): Since its inception in 1993, the University of Massachusetts Cancer Center has sought to elucidate new insights into normal and cancer cell biology. Investigators based at U Mass are beginning to translate this knowledge into clinical correlative studies and therapeutic approaches through the CALGB. For example, Dr. Mary-Ellen Taplin has described specific androgen receptor gene mutations that may target more effective treatments for hormone independent prostate cancer. These initial studies constitute one of the funded Correlative Science Studies through the CALGB and comprises one of the CALGB Core Labs. Based on our experience and substantial base in hematopoietic cell biology, a major focus of the U Mass Cancer Center has been in transplantion biology. Efforts have centered on (1) determining factors that enhance engraftment, (2) the development of entirely new transplant models using minimal myeloablation, (3) cord blood transplantation, (4) NOD-SCID preclinical transplant models to detect minimal residual disease, and (5) gene therapy approaches such as MDR1 transfer into normal hematopoietic stem cells. Many principles of hematopoietic stem cell biology "are now being applied to solid organ systems, with investigators at U Mass evaluating growth characteristics of both normal and neoplastic cells by defining the malignant stem cell" in solid tumor systems and defining autocrine and paracrine loop pathways of growth control. Stem cell "studies in breast cancer, prostate cancer, and glioblastoma" are ongoing and may provide important clinical correlative studies as companion studies to CALGB treatment protocols. Our Group Activities and Scientific contributions have increased significantly in the past four years. U Mass investigators in CALGB have contributed substantially to activities in Transplant, Breast Cancer, Prostate Cancer, Surgery, and Gastrointestinal Cancer. Administrative contributions through the Audit committee and other ad hoc committees have been substantial. Major efforts have led to improvement in accrual to Group Studies and improvement in the quality of data submitted on CALGB clinical trials.